Dapagliflozin
Dapagliflozin 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Renal Insufficiency, Chronic。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
11 项
已进入 III/IV 期
18 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- AstraZeneca
- University of Oklahoma
- Central Hospital, Nancy, France
- Minneapolis Heart Institute Foundation
- 4th Military Clinical Hospital with Polyclinic, Poland
- The First Affiliated Hospital of Soochow University
- University of Erlangen-Nürnberg Medical School
- University Health Network, Toronto
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、法国、Poland、中国、德国、加拿大、South Korea、India、Brazil、Egypt、中国香港、Mexico
正在招募患者的 Dapagliflozin 研究
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
III 期招募中美国NCT05174052Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List
不适用招募中法国NCT06868797Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
II 期招募中美国NCT05305911CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL
III 期招募中PolandNCT06304857Dapagliflozin in Allo-HCT for aGVHD
II 期招募中中国NCT06626737Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation
IV 期招募中德国NCT06560801The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
II 期招募中加拿大NCT05938712A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)
I 期招募中South KoreaNCT07083388Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
IV 期招募中IndiaNCT06676384Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease
I 期招募中美国NCT05762952Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes
II 期 / III 期招募中BrazilNCT06286878Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity
II 期招募中EgyptNCT06427226Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial
IV 期招募中中国香港NCT06668389CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
II 期招募中美国NCT06762964SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease
II 期招募中中国香港NCT06155604DapagliFLOzin in Renal AL Amyloidosis (FLORAL)
II 期招募中美国NCT06420167Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
IV 期招募中美国NCT06140537Epicardial Cardiac Fat-CT (EPIC-CT)
III 期招募中MexicoNCT07297589Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease
IV 期招募中MexicoNCT07405216Improving Coronary Vascular Health in Women
II 期招募中美国NCT06843902SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus
IV 期招募中中国香港NCT06364930"The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease"
不适用招募中EgyptNCT06520891Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
III 期招募中美国Argentina澳大利亚BrazilNCT06677060Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
不适用招募中美国NCT02969798
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。